



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/09745 (43) International Publication Date: 24 February 2000 (24.02.00)																																	
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border-right: 1px solid black; padding-right: 10px;"> (21) International Application Number: PCT/CA99/00733 (22) International Filing Date: 9 August 1999 (09.08.99) (30) Priority Data: 2,245,039 13 August 1998 (13.08.98) CA (71) Applicants (for all designated States except US): CANADIAN BLOOD SERVICES [CA/CA]; 1800 Alta Vista, Ottawa, Ontario K1G 4J5 (CA). HEMA-QUEBEC [CA/CA]; 2535, Boulevard Laurier, Sainte-Foy, Québec G1V 4M3 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): HU, Yu-Wen [CA/CA]; 79F Glen Park Drive, Gloucester, Ontario K1B 3Z2 (CA). (74) Agents: SWABEY OGILVY RENAULT et al.; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA). </td> <td style="width: 50%; vertical-align: top; padding-left: 10px;"> (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/CA99/00733 (22) International Filing Date: 9 August 1999 (09.08.99) (30) Priority Data: 2,245,039 13 August 1998 (13.08.98) CA (71) Applicants (for all designated States except US): CANADIAN BLOOD SERVICES [CA/CA]; 1800 Alta Vista, Ottawa, Ontario K1G 4J5 (CA). HEMA-QUEBEC [CA/CA]; 2535, Boulevard Laurier, Sainte-Foy, Québec G1V 4M3 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): HU, Yu-Wen [CA/CA]; 79F Glen Park Drive, Gloucester, Ontario K1B 3Z2 (CA). (74) Agents: SWABEY OGILVY RENAULT et al.; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>																															
(21) International Application Number: PCT/CA99/00733 (22) International Filing Date: 9 August 1999 (09.08.99) (30) Priority Data: 2,245,039 13 August 1998 (13.08.98) CA (71) Applicants (for all designated States except US): CANADIAN BLOOD SERVICES [CA/CA]; 1800 Alta Vista, Ottawa, Ontario K1G 4J5 (CA). HEMA-QUEBEC [CA/CA]; 2535, Boulevard Laurier, Sainte-Foy, Québec G1V 4M3 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): HU, Yu-Wen [CA/CA]; 79F Glen Park Drive, Gloucester, Ontario K1B 3Z2 (CA). (74) Agents: SWABEY OGILVY RENAULT et al.; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>																																		
(54) Title: PRIMER-SPECIFIC AND MISPAIR EXTENSION ASSAY FOR IDENTIFYING GENE VARIATION																																			
<table style="width: 100%; border: none;"> <thead> <tr> <th style="text-align: left; width: 20%;">dNTPs</th> <th style="text-align: left; width: 50%;">Primer</th> <th style="text-align: left; width: 30%;">Expected base extension</th> </tr> </thead> <tbody> <tr> <td>ATC</td> <td><u>Primer</u> →T CAXX</td> <td>3</td> </tr> <tr> <td>ATG</td> <td><u>Primer</u> →T X-XX</td> <td>1</td> </tr> <tr> <td>ACG</td> <td><u>Primer</u> →X-X</td> <td>0</td> </tr> <tr> <td>TCG</td> <td><u>Primer</u> →T CX--X</td> <td>2</td> </tr> <tr> <td colspan="3">WT-----A GTCCACATCCT---- (SEQ ID NO:16)</td> </tr> <tr> <td>ATC</td> <td><u>Primer</u> →X X</td> <td>0</td> </tr> <tr> <td>ATG</td> <td><u>Primer</u> →G XX</td> <td>1</td> </tr> <tr> <td>ACG</td> <td><u>Primer</u> →G CAGGX-X</td> <td>5</td> </tr> <tr> <td>TCG</td> <td><u>Primer</u> →G CX--X</td> <td>2</td> </tr> <tr> <td colspan="3">MU-----C GTCCACATCCT---- (SEQ ID NO:17)</td> </tr> </tbody> </table>			dNTPs	Primer	Expected base extension	ATC	<u>Primer</u> →T CAXX	3	ATG	<u>Primer</u> →T X-XX	1	ACG	<u>Primer</u> →X-X	0	TCG	<u>Primer</u> →T CX--X	2	WT-----A GTCCACATCCT---- (SEQ ID NO:16)			ATC	<u>Primer</u> →X X	0	ATG	<u>Primer</u> →G XX	1	ACG	<u>Primer</u> →G CAGGX-X	5	TCG	<u>Primer</u> →G CX--X	2	MU-----C GTCCACATCCT---- (SEQ ID NO:17)		
dNTPs	Primer	Expected base extension																																	
ATC	<u>Primer</u> →T CAXX	3																																	
ATG	<u>Primer</u> →T X-XX	1																																	
ACG	<u>Primer</u> →X-X	0																																	
TCG	<u>Primer</u> →T CX--X	2																																	
WT-----A GTCCACATCCT---- (SEQ ID NO:16)																																			
ATC	<u>Primer</u> →X X	0																																	
ATG	<u>Primer</u> →G XX	1																																	
ACG	<u>Primer</u> →G CAGGX-X	5																																	
TCG	<u>Primer</u> →G CX--X	2																																	
MU-----C GTCCACATCCT---- (SEQ ID NO:17)																																			
(57) Abstract																																			
<p>The invention relates to primer-specific and mispair extension assay for identifying gene variations, such as in different genotypes or subtypes of a given genotype. The assay comprises the steps of a) extending a nucleic acid sequence from a patient sample with a polymerase using a primer specific for a genotype to be determined and an incomplete set of dNTPs, under suitable conditions for obtaining extension products of the primer; b) characterizing the extension products; and c) comparing the extension products with known nucleic acid sequences of various genotypes for determining the genotype of the nucleic acid sequence extended. In the assay of the present invention, at least one of the primer or the dNTPs is labeled.</p>																																			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CJ	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PRIMER-SPECIFIC AND MISPAIR EXTENSION ASSAY
FOR IDENTIFYING GENE VARIATION

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to primer-specific and mispair extension assay for identifying gene variations, such as in different genotypes or subtypes of a given genotype.

10 (b) Description of Prior Art

Current genotyping systems are technically complex, time-consuming and error-prone in the detection of a single nucleotide variation and low level heterozygotes.

15 Despite current genotyping systems such as fragment length polymorphism analysis (RFLP), hybridization (e.g. line probe assay, LiPA), selective DNA amplification by PCR-type specific primers (Okamoto, H., et al., *J. Gen. Virol.* 73: 673, 678, 1992)
20 and direct DNA sequencing having been useful in general, some technical problems still remain and limits their applications.

Development of viral resistance to antiviral drugs used for treatment of HIV-1 infection is an
25 important cause of treatment failure (Coffin JM., *Sciences*, 267: 483-489, 1995). In addition, drug resistance mutations can give rise to selective cross-resistance to other antiviral drugs, which has limited the options available for alternative antiviral
30 regimens (Cohen OJ, and Fauci AS., *N. Engl. J. Med.*, 339: 341-243, 1998). Thus genotypic drug resistance testing plays an important role in selecting an initial antiviral regimen and changing therapy with alternate regimens as the need arises. However, current
35 genotyping assays, including direct DNA sequencing, yield information on only the predominant viral

quasispecies due to the inability of these assays to detect low levels of viral variants (Günthard HF, et al., *AIDS Res. Hum. Retroviruses*, 14: 869-876, 1998). ABI automated sequencer was able to detect mutants at levels of 10-50% in an artificially mixed sample only when the mixes were analyzed by editing the sequences manually. Hybridization based high-density oligonucleotide arrays (GeneChip) (Deeks SG, Abrams DI., *Lancet*, 349: 1489-1490, 1997) were less sensitive than the ABI sequencer, being able to detect mutations at levels of 25-75% in the mix (Günthard HF, et al., *AIDS Res. Hum. Retroviruses*, 14: 869-876, 1998). Similar results were obtained using an automated DNA sequencer (Visible Genetics) (Hu YW, et al., Reliable detection of mixed HCV genotype infections using a novel genotyping assay. 5th International Meeting on Viral Hepatitis C Virus and Related Viruses, Molecular Virology and Pathogenesis, Venezia, Italy, 1998). Line Probe Assay (LiPA), which uses reverse hybridization technology, is relatively rapid and could detect mutants at levels as low as 5% (Stuyver L, et al., *Antimicrob. Agents Chemother.*, 41: 284-291, 1997), but again may not be suitable for detection of mixed genotypes because it may give no results due to nearby polymorphism that impair hybridization (Stuyver L, et al., *Antimicrob. Agents Chemother.*, 41: 284-291, 1997). Moreover, in 40% of the samples tested, LiPA failed to yield correct results for some of the drug resistance mutations (Puchhammer-Stockl E, et al., *J. Med. Virol.*, 57: 283-289, 1999). Population based sequencing (i.e. cloning and sequencing) is the gold standard method for detection of minor drug resistance mutants. Unfortunately, it is impractical for clinics and large cohort studies.

For most indirect DNA sequencing genotyping systems, a common weakness is that they are not as accurate as direct DNA sequencing analysis in particular for detection of a single nucleotide mutation or variation, resulting in considerable instances of errors or inconsistent results (Andonov, A., et al., *J. Clin. Microbiol.* 32: 2031-2034, 1994); (Tuveri, R., et al., *Journal of Medical Virology* 51: 36-41 (1997); Okamoto, H., et al., *J. Virol. Methods* 57: 31 45 002-16, 1996). Although direct DNA sequencing is the most reliable method for genotyping, this is not practical for large cohort studies.

Another major limitation of all current genotyping systems, including direct DNA sequencing is that they can not reliably detect low level of heterozygotes (Tuveri, R., et al., *Journal of Medical Virology* 51: 36-41, 1997); (Lau, J.Y., et al., *J. Infect. Dis.* 171: 281-289, 1995); (Forns, X., et al., *J. Clin. Microbiology.* 34-10: 2516-2521, 1996); or mixed genotype infectious (Tuveri, R., et al., *Journal of Medical Virology* 51: 36-41, 1997); (Lau, J.Y., et al., *J. Infect. Dis.* 171: 281-289, 1995); (Forns, X., et al., *J. Clin. Microbiology.* 34-10: 2516-2521, 1996).

HCV was recognized as the major etiologic agent of blood borne non-A, non-B hepatitis soon after the virus was identified in 1989. As an RNA virus, HCV shows great genetic variability, resulting in the existence of types, subtypes and quasispecies. At present, 11 types and at least 50 subtypes have been described. However, types 1a, 1b, 2a, 2b and 3a have been found to be generally the most prevalent (Simmonds, P., *Hepatology* 21: 570-582, 1995). Subtype 1b is the most common genotype found in Japan (Okamoto, H., et al., *J. Gen. Virol.* 73: 673, 678, 1992) and European countries while subtypes 1a and 1b are the

most common genotypes in the United States (Lau, J.Y., et al., *J. Infect. Dis.* 171: 281-289, 1995) and Canada, (Andonov, A., et al., *J. Clin. Microbiol.* 32: 2031-2034, 1994). Viruses of various genotypes contain
5 different antigenic properties, which have potentially important consequences for the development of a vaccine and for antibody screening tests. Also, the disease severity and response to interferon may be influenced by the virus types and subtypes (Simmonds, *Hepatology*
10 21: 570-582, (1995). Subtype 1b was reported to be associated with a high severity of the disease and low response to interferon (Simmonds, *Hepatology* 21: 570-582, (1995). It is apparent that a rapid, simple, accurate and inexpensive genotyping method is urgently
15 needed.

Amplification refractory mutation system (ARMS) (Newton, C.R., et al., *Nucl. Acids Res.* 17: 2503-2516), improved the methods used in the prior art for typing the five most common genotypes (Pistello, M., et al.,
20 *J. Clin. Microbiol.* 32: 232-234, 1994). ARMS was developed for PCR detection of any point mutation in DNA using Taq DNA polymerase (Newton, C.R., et al., *Nucl. Acids Res.* 17: 2503-2516). It is based on the principle that oligonucleotides with a mismatched 3'-
25 residue would not function as primers in PCR under controlled conditions. In some cases, however, the specificity of ARMS was not sufficient to give a correct diagnosis. The problem with non-specific reactivities still remains with the type-specific
30 primer PCR method for HCV genotyping, even with the improvement using ARMS.

It is apparent that the major cause of the nonspecific reactivities found in these assays is related to the use of Taq DNA polymerase due to its
35 lack of 3'→5' exonuclease activity. This inaccuracy

results in base substitutions, transitions, tranversions, frame shifts or deletion mutations during DNA synthesis. Consequently, mispairs can be frequently formed, and Tag polymerase would be able to continue synthesizing DNA by addition of the next correct nucleotide on the template (Lau, J.Y., et al., *J. Infect. Dis.* 171: 281-289, 1995). Even after reaching the end of the template, several more nucleotides can be added to the extended primer because most DNA polymerases, including Tag and retroviral reverse transcriptase (RT), have a non-template dependent DNA synthesis activity (i.e. terminal deoxynucleotide transferase activity) (Clark, J.M., *Nucleic Acids Res.* 16: 9677; and Patel, P.H., et al., *Proc. Natl. Acad. Sci. U.S.A.* 91: 549-553). Therefore, the nonspecific reaction cannot be avoided with either ARMS or the methods based on ARMS using Tag DNA polymerase.

Two thermostable DNA polymerases *pfu* (*pyrococcus furiosus*) (Lundberg, K.S., et al., *Pyrococcus furiosus*. *Gene* 108: 1-6, 1991), and *TLI/Vent* (*Thermococcus litoralis*) (Neuner, A., et al., *J. Arch. Microbiol.*, 153: 205-207) exhibit 3'→5' proofreading exonuclease activity. This ensures a high degree of amplification fidelity during DNA polymerization. Unlike Vent, the *pfu* 3'→5' exonuclease activity peaks sharply at its optimal polymerization temperature (75°C to 80°C), minimizing undesirable primer-degradation activity (Lundberg, K.S., et al., *Gene* 108: 1-6, 1991). *pfu* DNA polymerase also does not exhibit terminal deoxynucleotidyl-transferase (TDT) activity, which was reported to be involved in the high mutation rate of DNA during DNA polymerization.

It would be highly desirable to be provided with a simple assay or method to overcome many of these limitations of current DNA genotyping systems.

It would be highly desirable to be provided
5 with genotypic assays that possess greater accuracy and sensitivity for detection of minor drug resistant subpopulations of HIV-1 in the early stages of resistance evolution.

10 SUMMARY OF THE INVENTION

One aim of the present invention is to provide a novel primer specific and mispair extension assay (PSMEA) for the determination of genotypes and subtypes.

15 Another aim of the present invention is to provide a primer specific and mispair extension assay (PSMEA) to detect nucleotide variations in any known gene sequence using *pfu* DNA polymerase in the presence of an incomplete set of dNTPs, and only a single
20 primer.

Another aim of the present invention is to provide a tool for reliable detection of mixed genotype infectius.

Another aim of the present invention is to
25 provide a sensitive tool for detection of low levels of drug resistant mutants in patients being treated with antiviral drugs.

Another aim of the present invention is to provide a tool for accurate genotyping.

30 In accordance with the present invention, there is provided a primer-specific and mispair extension assay for the determination of genotype. The assay comprises the steps of:

a) extending a nucleic acid sequence from a
35 patient sample with a polymerase, more preferably a PFU

DNA polymerase, using a primer specific for a genotype to be determined and an incomplete set of dNTPs, under suitable conditions for obtaining extension products of the primer, whereby at least one of the primer or the
5 dNTPs is labeled;

b) characterizing the extension products; and

c) comparing the extension products with known nucleic acid sequences of various genotypes for determining the genotype of the nucleic acid sequence
10 extended.

Preferably, the step of characterizing the extension products comprises the step of separating by size said extension products. More preferably, the step of characterizing the extension products further
15 comprises after the step of separating by size the extension products the step of sequencing the extension products.

Alternatively, the assay may further comprise before step a) the step of amplifying the nucleic acid
20 sequence.

Preferably, the incomplete set of dNTPs contains two or three different types of nucleotides.

In a preferred embodiment, the primer is labeled with a radioactive label or a fluorescent
25 label.

In another embodiment, one of the dNTPs is labeled with a radioactive label or a fluorescent label.

In accordance with the present invention, there
30 is provided a novel genotyping system, primer specific and mispair extension analysis (PSMEA) using preferably the unique 3' to 5' exonuclease proofreading properties of pfu DNA polymerase with an incomplete set of dNTPs and only a single primer.

Also in accordance with one embodiment of the present invention there is provided a primer-specific and mispair extension assay for the determination of genotype and detection of low level mixed genotype injections or heterozygotes. The assay comprises the steps of:

- a) extending a DNA sequence amplified from a patient sample with *PFU* DNA polymerase using a primer specific for a genotype to be determined and an incomplete set of dNTPs, under suitable conditions for obtaining extension of the primer, whereby at least one of the primer or one of the dNTPs is labeled;
- b) separating the extended DNA sequences obtained in step a); and
- c) detecting the separated extended DNA sequences; and
- d) comparing the extended DNA sequences with known DNA sequences of various genotypes for determining the genotype of the DNA sequences extended.

The primer may be end-labeled with a label or one of the dNTPs can be labeled with a label. The label can be a radioactive or fluorescent label.

Preferably, the steps a), b), c), and d) as described above are automated.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates characteristics of primer specific and mispair extension by *pfu* and *Taq*. DNA polymerase;

Fig. 2 illustrates nucleotide deletions and insertions by PSMEA with primer 6AR-1 and 6AR-2 extensions by *pfu* on templates 1a and 6a);

Fig. 3 illustrates a comparison of the sensitivity between PSMEA and direct DNA sequencing in detection of mixed genotypes;

Fig. 4 illustrates a typical profile of unlabelled primer extensions by *pfu* on HCV templates for types 1a, 1b, 2a, 2b, 3a and 3b using ³²P-labeled dCTP and dGTP;

5 Figs. 5A and 5B illustrate the detection of HIV-1 drug resistant mutant V82A and wild type V82 using a universal primer and four sets of dNTPs;

10 Figs. 6A and 6B illustrates the detection of HIV-1 drug resistant mutant L63P and wild type L63 using matched and mismatched pairs at the 3' end of the primers in PSMEA;

15 Figs. 7A and 7B illustrates the detection of HIV-1 drug resistant L90M and wild type L90 using matched and mismatched pairs at the 3' end of the primers; and

Fig. 8 illustrates the sensitivity of PSMEA for detecting low levels of HIV-1 drug resistant mutant with a defined mix of mutant V82I and wild type V82.

20 DETAILED DESCRIPTION OF THE INVENTION

In accordance with one embodiment of the invention, there is provided a novel primer specific and mispair extension assay (PSMEA) for the determination of genotypes, and more preferably
25 Hepatitis C virus (HCV) genotypes and subtypes.

PSMEA is used to detect nucleotide variations in any known gene sequence using *pfu* DNA polymerase in the presence of an incomplete set of dNTPs. To test the feasibility of PSMEA, the 5' UR of the HCV genome, known for being highly conservative, was used as a
30 model for analysis of the nucleotide variation in determining the type and subtype of the virus. The results obtained demonstrate that PSMEA is a rapid, simple and accurate method for HCV genotyping.

In the 5' UR of the HCV genome, six major genotypes and some subtypes can be classified by the nucleotide variation in this region (Simmonds, P., *Hepatology* 21: 570-582, 1995); (Stuyver, L., et al., *J. Clin. Microbiol.* 34: 2259-2266, 1996).

The PSMEA of the present invention is a simple method with great potential in accurately detecting nucleotide mutations and which may be used for detecting nucleotide variations in any known gene sequence.

PSMEA is based on the unique properties of 3'→5' proofreading activity in a reaction with incomplete set of dNTPs. Under such reaction condition in accordance with one embodiment of the invention, *pfu* is extremely discriminative in nucleotide incorporation and proofreading at the initiation step of DNA synthesis, allowing for an accurate detection of nucleotide variation and heterozygotes in PSMEA.

It is known that under this reaction condition, mispair formation and extension occur during DNA synthesis when using reverse transcriptase and DNA polymerases, including enzymes that exhibit 3'→5' proofreading exonuclease activity (Perinno, F., et al., *Proc. Natl. Acad. Sci. USA.* 86: 8343-8347, 1989); (Reha-Krantz, L.J., et al., *Proc. Natl. Acad. Sci. USA.* 88: 2417-2421, 1991). However, the frequency of mispair formation and extension depends on whether the polymerase possesses 3'→5' exonuclease activity, the concentration of nucleotide substrates and the composition of the mispairs (Reha-Krantz, et al., *Proc. Natl. Acad. Sci. USA.* 88: 2417-2421, 1991). Accordingly, the characteristics of primer specific and mispair extension by thermostable DNA polymerases including *pfu* (*Pyrococcus furiosus*) (Lundberg, K.S., et al., *Gene* 108: 1-6, 1991), *Taq* (*Thermus aquaticus*),

(Saiki, R.K., et al., *Science*. 239: 487, 1988), and TLI/Vent (*Thermococcus litoralis*) (Neuner, A., et al., *J. Arch. Microbiol.*, 153: 205-207) were further investigated. Several characteristics of primer
5 specific and mispair extension by *pfu* were observed and found to be useful for reliable detection of nucleotide variation, deletion and insertion as well as heterozygotes.

In accordance with a preferred embodiment of
10 the invention, the accuracy was evaluated by assaying the nucleotide variations between genotypes in the 5' untranslated region (5' UR) of the hepatitis C virus (HCV) genome. Mixed infections with more than one genotype of HCV were used for comparison of the
15 sensitivity of PSMEA with other assays in the detection of heterozygotes. The feasibility of the method of the present invention for large cohort studies was demonstrated by genotyping a total of two hundred and forty five (245) HCV isolates. The results show that
20 PSMEA is an extraordinary accurate system to identify nucleotide variation for genotyping and detecting heterozygous molecules, readily applicable to routine use.

The design of PSMEA in accordance with a
25 preferred embodiment of the invention is based on a single primer extension by the *pfu* DNA polymerase in the presence of only dGTP and dGTP, permitting accurate detection of nucleotide variations in the 5' untranslated region (5'UR) of the HCV genome. In
30 accordance with one embodiment of the invention, the HCV genotypes from ninety-six (96) patients and blood donors with HCV infection were determined by PSMEA. Seventy-four (74) of the samples were also genotyped by either the line probe assay (LiPA) or restriction
35 fragment length polymorphism (RFLP) methods. Genotypes

were confirmed by nucleotide sequencing as required. HCV Isolates, including types and subtypes 1a, 1b, 2a, 2b, 2c, 3a, 3b, 4a, 5a, and 6a, were clearly identified by the PSMEA of the present invention. All of the
5 types and subtypes determined by PSMEA were matched with those identified by LiPA or RFLP. Five (5) isolates of subtypes 1a and 1b that could not be typed by LiPA were clearly identified by the PSMEA of the present invention.

10 The primers used in the present invention were designed to meet the following requirements: 1) the sequence of primer binding site on template should be a type or subtype specific; 2) primers used for PSMEA should exhibit a similar melting temperature. In
15 accordance with the present invention, 11 primers were designed for HCV genotyping with PSMEA (Table 1).

Table 1. Nucleotide sequence of the primers for PSMEA

Primers	Position		Sequence from 5' to 3'
For PCR (universal)			
1st round	-302 to -278		CTC CCC TGT GAG GAA CTA CTG TCTT (Sense)
	-50 to -31		CTC GCA AGC ACC CTA TCA GG (Antisense)
2nd round	-204 to -175		CCA TAG TGG TCT GCG GAA CCG GTG AGT ACAC (Sense)
	-91 to -74		CCC AAC ACT ACT CGG CTA (Antisense)
For PSMEA			
IAB	-131 to -111		CTC AAT GCC TGG AGA TTT GGG
I	-176 to -157		CAC CGG AAT TGC CAG GAC GA
IBR'	-98 to -78		ACA CTA CTC GGC TAG CAG TCT
2A	-134 to -114		CCA CTC TAT GCC CGG TCA TTT
2B	-128 to -108		TAT GTC CGG TCA TTT GGG CAC
2C	-133 to -113		CAC TCT GTG CCC GGC CAT TTG
3A	-175 to -157		ACC GGA ATC GCT GGG GTG A
3B	-175 to -157		ACC GGA ATC GCC GGG ATG A
3R'	-99 to -79		CAC TAC TCG GCT AGT GAT CTC
5AR'	-236 to -218		GGG GGT CCT GGA GGC TGT T
6AR'	-145 to -125		CAT TGA GCG GGT TTG ATC CAA T

† Antisense primer

Fig. 1 illustrates preferred characteristics of primer specific and mispair extension by *pfu*.

In Fig. 1, I illustrates ³²P-labeled primer extensions by *pfu* on template 1b in the presence of dCTP and dGTP (Fig. 1, I-1 and 1, I-2) used as markers for the length of primers and extended products. II illustrates the use of ³²P-labeled dNTPs instead of labeled primers for PSMEA under the same reaction conditions, showing the difference in primer extension between genotypes 1a and 1b (Fig. 1, II-1, II-2, II-3 and II-4). III illustrates mispair formation and extension by *Taq* on template 1a with ³²P-labeled primers 1AB and 1BR (Fig. 1, III-1 and III-2). I', II' and III' illustrate the nucleotide sequences extended on templates 1a and 1b. Primer 1AB extended on the antisense strand of templates 1a and 1b. X, XX and XXX represent the sites of nucleotide mismatches that terminated primer extension. → represents a nucleotide at the 3' end of the primer that is complementary to the opposite nucleotide in the template. (A), (C), (G) or (T) denotes the position of the nucleotide when a mispair is produced. -113, -108 and -99 are the nucleotide positions in 5'UR of HCV. The underlined sequence indicates the primer binding sites. The signs in this figure are used for all other figures.

A mismatched pair with nucleotide A at position -99 of the template HCV genotype 1a, that is opposite the first nucleotide to be incorporated at the 3' end of primer could not be produced, and subsequently aborted primer extension by *pfu* in the presence of dCTP and dGTP (Fig. 1, I-1). Under the same reaction conditions, the primer extended on the template of genotype 1b because nucleotide A becomes G at position -99 (Fig. 1, I-2), differentiating between genotypes 1a

and 1b with this single nucleotide variation that is the only difference in the 5' UR between the two genotypes.

FIG. 1 illustrates the alignment of the 5' UR nucleotide sequences of HCV subtypes 1a and 1b, showing the homologous sequence(----) and the difference of the nucleotide at position of -99(A for 1a and G for 1b). The primer extension stopped at position of -99 where a mismatched pair(s) exists (X) in. The arrow (→) represents a nucleotide at 3' end of the primers that is complementary to the opposite nucleotide in the template. The parenthesis () denotes that a nucleotide mispair occurred.

The absence of mispair formation and extension at position -99 is due to pfu 3'→5' exonuclease proofreading activity that sharply peaks up at its optimal polymerization temperature, removing the mismatched nucleotide added at the initiation step of primer extension. It is apparently different from the 3'→5' exonuclease proofreading activity of other DNA polymerases such as pol- α and T4 in the primer mispair extension reaction. The mispair at the initiation site of DNA synthesizing can be produced with high frequency by these DNA polymerases in the primer mispair formation and extension reaction (Perinno, F., et al., *Proc. Natl. Acad. Sci. USA.* 86:8343-8347, 1989), (Reha-Krantz, L.J., Set al., *Proc. Natl. Acad. Sci. USA.* 88:2417-2421, 1991).

Taq DNA polymerase without 3'→5' exonuclease proofreading activities is used in virtually all PCR based genotyping assays (Okamoto, H., et al., *J. Gen. Virol.* 73: 673, 678, (1992), (Newton, C.R., et al., *Nucl. Acids Res.*, 17: 2503-2516). The unreliability caused by cross reactivity and wrong priming has been a big concern (Lau, J.Y., et al., *J. Infect. Dis.* 171:

281-289, 1995), and Forns, X., et al., *J. Clin. Microbiology*. 34-10: 2516-2521, 1996). When *Taq* is used instead of *pfu*, with the other conditions of the assay being the same, the primer 1BR extension took place on template 1a despite a mismatched pair existing at primer extension initiation site (-99) (Fig. 1-III-2). This clearly indicates that the major cause of these nonspecific reactivities is due to the infidelity of *Taq* during the initiation of DNA synthesis (Perinno, F., et al., *Proc. Natl. Acad. Sci. USA*. 86: 8343-8347, 1989).

In addition, since most DNA polymerases including *Taq* and reverse transcriptase of retroviruses exhibit a non-template dependent DNA synthesis activity (i.e. terminal deoxynucleotide transferase activity, TDT), several more nucleotides can be added to the 3' end of the primer. (i.e. single strand DNA) (Clark, J.M., *Nucleic Acids Res.* 16: 9677), (Patel, P.H., et al., *Proc. Natl. Acad. Sci. U.S.A.* 91: 549-553). Thus *Taq* would be able to continue synthesizing DNA by addition of a correct paired nucleotide next to the mispaired nucleotide, in particular to the nucleotide in the A:C mispair that can be formed and extended more efficiently than other mispairs (Perinno, F., et al., *Proc. Natl. Acad. Sci. USA*. 86: 8343-8347, 1989), (Newton, C.R., et al., *Nucl. Acids Res.* 17: 2503-2516). A DNA strand with mismatched nucleotides would be generated and then act as a template that would be subsequently re-amplified, generating a large number of non-specific DNA molecules. Therefore, the nonspecific reaction can not be completely avoided with the methods based on DNA amplification with primer-specific PCR using *Taq* DNA polymerase. In contrast, in PSMEA, only a single primer is used, so that the extended primer cannot be re-amplified, and any mispairs, including A:C

in front of the 3' end of primer could completely stop primer extension. *TLI/Vent* DNA polymerase exhibits 3'→5' proofreading exonuclease activity, however, unlike *pfu*, *TLI/Vent* severely degraded single stranded DNA (i.e. primer) in PSMEA.

In Figs. 1, I-1, primer extension was performed using *pfu* with labeled primers (I-I), *pfu* with labeled dNTPs (I-II), and *Taq* with labeled primers (I-III). The symbol ↑ represents where the nucleotide incorporation starts. The symbol (X) denotes a stop of primer extension caused by the nucleotide mispair(s).

The second feature of specific and mispair extension by *pfu* is that one correct pairing followed by more than one mispair in front of the 3' end of the primer is not sufficient for primer extension (Figs. 2, I-1 and I-2), at least two consecutive correct pairings are required (Fig. 2, I-4 and II-2). This provides a means to identify nucleotide deletion and insertion as well as multiple nucleotide variations or mutations in PSMEA.

In Fig. 2, Primer 6AR-1 could not be extended with template 1a when using either dCTP plus dTTP, or dCTP plus dGTP as substrates due to a CA deletion (...), resulting either in a mispair at nucleotide position -145 in front of the 3' end of primer (I-1) or in only one matched pairing at the position. (I-2). Primer 6AR-1 could not be extended on template 6a when using dCTP and dGTP (I-3). However, the primer was extended by three bases with template 6a using dGTP and dTTP which matched the nucleotides in the CA insertion (CA) in template 6a (I-4). Primer 6AR-2 was extended when using template 6a (II-1 and II-2), but not with template 1a using either dATP, dCTP and dGTP or only dGTP (II-3 and II-4). The symbol ↔ denotes the

removal of the first nucleotide mismatched at the 3' end of the primer.

As seen in Fig. 2, there is a unique CA insertion in the 5' UR of HCV genotype 6a. Use of the CA insertion can differentiate between 6a and other genotypes. In the instant application, the CA insertion is used as an example to show how nucleotide deletion and insertion could be identified. Based on the flanking nucleotide sequence of the CA insertion, two primers were designed. A first primer 6AR-1, located in the region before a CA insertion in HCV genotype 6a was extended only when using the correctly paired dNTPs (i.e. dGTP and dTTP) (Fig. 2, I-4), but not those dNTPs (dCTP and dGTP) (Fig. 2, I-3) that mismatched with the nucleotide A in the CA insertion. The second primer 6AR-2 was designed with the first nucleotide at its 3' end being matched with the first nucleotide A in the CA insertion of template 6a. Thus the primer extended two bases or 11 bases on template 6a, depending on the substrates of dNTPs used (Fig. 2, II-1 and II-2), but not on template 1a due to a CA deletion that results in a 3' mispaired residue being removed after primer binding (Fig. 2, II-3 and II-4).

In accordance with the present invention, multiple nucleotide variation or mutation can be identified. For example, a unique TCA motif that is specific to genotype 3a and 3b could be identified and is used for differentiation between the two genotypes and other genotypes.

Like mispair formation and extension by T4 DNA polymerase (Wilber, J. C., et al., M. S. Reverse transcriptase-PCR for hepatitis C virus RNA, p. 327-331. In D. H. Persing, T.F. Smith, F.C. Tenover, and T.J. White (ed.), Diagnostic Molecular Microbiology: Principles and Applications. American Society for

Microbiology, Washington D.C. 1993), any two or more consecutive mispairs could completely terminate primer extension by *pfu* because of its 3'→5' proofreading activity (Figs. 1, II-2 and 2, I-3 and II-2). It was also found that two or more mispairs, but separated with one or two correct base pairs (Figs. 1, II-1 and 2, II-1) also could terminate primer extension by *pfu*. Use of the termination point caused by these mispairs as well as primer specific and mispair extensions on templates by *pfu* provided reliable information on nucleotide sequence in the given region of the 5' UR of HCV.

The highest molecular weight band shown on the sequencing gels represents the longest sequence extended to the termination point that is specific to each of the HCV genotypes. As indicated in Fig. 1, II, for example, the highest band represents the primer 1AB extended to the nucleotide C at nucleotide position -100 before the termination point at position -99 and -98 that would produce two mispairs with the two adjacent nucleotides A in template 1a, while the highest band represents the primer extended to the nucleotide G at -99 before the termination point at position -98 and -96 in template 1b, showing the single nucleotide difference between 1a and 1b. This is another way to identify a single point mutation or variation in PSMEA in accordance with the present invention.

Whatever dNTPs (i.e. one, two or three of the four dNTPs) are chosen, they must follow the "instruction" with the characteristics of primer specific and mispair extension by *pfu*.

The nucleotide incorporation rate of *pfu* is one fifth (1/5) of that of *Taq*. Thus *pfu*-based PCR applications require a minimum extension time of 2.0

minutes/kb. The efficiency of nucleotide incorporation by pfu is high enough for PSMEA in which only less than 20 bases of extension are required per cycle in the reaction. Over 50% of the excess primer with less
5 template (molecular ratio of primer and template 10:1) could be extended in a 20 cycle reaction, generating strong signals with either ³²P-labeled primer or dNTPs. Thus, PSMEA offers not only an advantage of superior accuracy over current indirect DNA genotyping systems,
10 but an extraordinary sensitivity for detection of mixed infections with different genotypes of HCV.

Direct DNA sequencing is routinely used as the gold standard method for confirmation of the results from other assays (Tuveri, R., et al., *Journal of*
15 *Medical Virology* 51: 36-41, 1997), (Forns, X., et al., *J. Clin. Microbiology*. 34-10: 2516-2521, 1996). In the present application, the sensitivity of PSMEA for identifying mixed infections was evaluated with direct DNA sequencing methods. In an experiment, the cDNAs
20 (PCR products) from genotypes 1b and 2a isolates were mixed in different proportions to mimic HCV mixed infections and heterozygotes. Fig. 3 shows that genotype 2a could be clearly identified by direct DNA sequencing only when it reached to 50% in proportion in
25 the mix. When 2a molecules consisted of less than 25%, only some of nucleotide variation points could be manually recognized, but was not conclusive for the identification of which genotype it was. However, 2a consisting as low as about 3% in the mix was clearly
30 detected by PSMEA, showing approximately 10 times more sensitivity than the direct DNA sequencing system.

To further confirm the sensitivity of PSMEA, three samples identified to contain two or three genotypes by PSMEA were analyzed by direct DNA
35 sequencing (Fig. 3, B) and the reverse hybridization

method. Results reveal that the presence of 2b was confirmed by the direct DNA sequencing method, but not by reverse hybridization method in the sample containing 1a as dominant population.

5 Fig. 3 presents autoradiography results in A and the date of a computer analysis of automated sequencing in A'. Different proportions of genotypes 1b and 2a: 0% to 100% (I), 50% to 50% (II), 75% to 25% (III), 87.5% to 12.5% (IV), 93.75% to 6.25% (V), and
10 96.875% to 3.125% (IV) in the mix were analyzed with PSMEA (A) and direct DNA sequencing (A'). Two genotypes, 1a and 2b, were identified in a thalassaemia patient sample by PSMEA (B). N in B represents the negative reaction with primer 6AR and the sample from
15 the thalassemia patient.

To evaluate the feasibility of PSMEA for large cohort studies, a total of two hundred and forty five (245) samples from HCV seropositive blood donors and patients with chronic hepatitis were genotyped by this
20 assay. The genotypes determined by PSMEA included 1a, 1b, 2a, 2b, 2c, 3a, 3b, 4, 5a and 6a. The typeable rate of these samples with PSMEA was 95.5%. Eighty (80) of them were also typed with other indirect or direct DNA sequencing genotyping methods. The
25 genotyping results from PSMEA were in 90-100% concordance with that from other genotyping methods including LiPA, RFLP and direct DNA sequencing. Less than 5% of untypeable samples were sequenced, indicating that those isolates being untypeable by
30 PSMEA were either HCV mutants or unclassified genotypes. Results have proven a great utility of PSMEA for large cohort studies on viral genotyping.

PSMEA has been further developed with an automatic and colorimetric format, creating a great
35 capacity to quickly genotype a large number of HCV

isolates not previously possible. Therefore, PSMEA has a great potential for the identification of nucleotide variations and heterozygotes in many areas such as virology, bacteriology, human genetics, epidemiology
5 and legal medicine.

When a type or subtype-specific sequence is available for designing the primer, for example primers 2A and 3A, no cross reactivities with other genotypes are observed in PSMEA. Consistent results were
10 obtained with primers 1AB, 2B, 2C, and 3R (Table 2).

Primer 1AB is universal for genotypes 1a and 1b (Fig. 1, III), differentiating the two genotypes from other genotypes except genotype 6a due to the homologous sequence in the region -131 and -99 between genotypes 1a/1b and 6a. Fortunately, a nucleotide A in the unique CA insertion between the nucleotide positions -145 and -144 in the 5' UR of 6a could be used as first paired nucleotide at the 3' end of primer 6AR, thus the primer specifically extended on template 6a, but not other genotypes (Fig. 2, I).

The primer could be bound on other genotypes, but could not be extended due to the CA deletion in these genotypes versus the insertion in 6a 5'UR. It was thus found that, for example, the primer 6AR-1 could not be extended because there a single C at position -145 which could be paired in presence in the presence of dTTP and dGTP, followed by three Ts in the template 1a, in the reaction (Fig. 2, I-1). However, the primer extended on template 6a in the same reaction conditions due to the presence of the two consecutive pairings C:G and A:T at positions between -145 and -144 (Fig. 2, I-4). Accordingly, the primer 6AR2 could be extended longer on template 6a when using three dNTPs (dATP, dGTP and dCTP), showing a stronger signal to differentiate 6a from other genotypes (Fig. 2, II-1). In the same manner, primer 5AR designed with a nucleotide variation at -236 was subtype specific.

As shown in Table 2, primer 3B that was originally designed for identification of genotype 3b exhibited cross reactivity with 4e in PSMEA due to the homologous sequence in the region -175 to -149 chosen between the two genotypes. Thus a small region (-99 to -79) that contains an unique TCA motif in 5'UR of genotypes 3a and 3b was used for designing the primer 3R. Thus by using primers 3A and 3R, genotypes 3a and

3b could be differentiated from other genotypes. Similarly, three genotypes 1a, 1b and 6a could clearly be identified with primer 1AB, 1BR and 6AR that exhibited a cross reactivity with 1AB. A total 11
5 genotypes including six major genotypes (1a, 1b, 2a, 2b, 3a, 3b) and some of uncommon genotypes (2c, 5a, 6a, 4a and 4e) in Canada could be identified by PSMEA using 11 primers (Table 2).

Extension of the mismatched 3' termini of DNA
10 is a major determinant of the infidelity of the DNA polymerases that have no 3'→5' exonuclease activity, (Pistello, M. et al., *J. Clin. Microbiol.* 32: 232-234). With the PSMEA of the present invention, by using 3'→5' exonuclease proofreading activity, high
15 detection specificity for nucleotide mutation or variation in a known gene has been achieved with the PSMEA of the present invention. A big advantage of this assay is that a single nucleotide variation, deletion and insertion can be accurately detected. In
20 the genome of many natural virus mutants or drug resistant mutants there may be only a single nucleotide mutation that has potential genetic or clinical significance. For example a substitution C for A at nucleotide position 1814 that destroys the precore
25 initiation codon, will prevent production of HBVeAg. In some of drug resistant mutants, a single nucleotide mutation could cause a failure of an antiviral therapy. PSMEA of the present invention can thus be used for rapid screening of those mutants.

30 A single point mutation could be associated with genetic disease in human such as a single point mutation resulting in an amino acid substitution (C282Y) in the gene, *HLA-H* for haemochromatosis, which was reported to be involved in iron metabolism
35 disorder. Such single point mutation are frequently

found in viruses. For example, a substitution C for A results in loss of precore initiation codon of hepatitis B virus, preventing e-antigen (HBeAg) synthesis.

5 The PSMEA of the present invention can be modified so as to replace radioactivity by a detectable label. Such a non-radioactive assay could be in the form of a colorimetric PSMEA in a microtiter-plate format.

10 The present invention will be more readily understood by referring to the following examples, which are given to illustrate the invention rather than to limit its scope.

15

EXAMPLE I

DETERMINATION OF HCV GENOTYPES

Primer extension reactions contained 20 ng primer, 20-30 ng PCR product, 20 mM of each dCTP and dGTP, 10 mCi of each ³²P-labeled dCTP and dGTP, 1.25
20 units pfu DNA polymerase and 10 ml 10X pfu reaction buffer (PDI). When 5'-end ³²P-labeled primers were used, the ³²P-labeled dCTP and dGTP were omitted, and 100 μM of each dCTP and dGTP were used in the reactions. The primer extensions were performed in a
25 reaction volume of 100 μl in a thermocycler (Perkin Elmer, GeneAmp 9600). Twenty (20) cycles consisting of a denaturation step at 94°C for 20 seconds, an annealing step at 64°C for 20 seconds and an extension step at 72°C for 35 seconds were performed. One
30 microliter of the primer extension products was mixed with 1 μL of the sequencing stop solution (Pharmacia Biotech) and electrophoresed on 8% polyacrylamide 8M urea TBE gels for one hour. Extension products were visualized by autoradiography.

For PCR amplification and sequence analysis, viral RNA was isolated from 100 ml of serum by treatment with RNazol B (Biotech Laboratories, Houston, Tex.) as previously described in Wilber, J. C., Johnson, P. J., and Urdea, M. S. Reverse transcriptase-PCR for hepatitis C virus RNA, p. 327-331. In D. H. Persing, T.F. Smith, F.C. Tenover, and T.J. White (ed.), Diagnostic Molecular Microbiology: Principles and Applications. American Society for Microbiology, Washington D.C. 1993. RT-PCR was performed as described by Bernier et al (Bernier, L., et al., *J. Clin. Microbiol.* 34: 2815-1818), with a set of primers that target highly conserved domains within the 5'-UR. The nucleotides and primers were removed from the PCR products with the QIAquick™ PCR Purification Kit (QIAGEN), using the procedure recommended by the product supplier. These purified PCR products were used for primer extension and automated sequencing analysis.

HCV isolates from patients with HCV infection were typed either by the improved Inno LiPA kit II™ using the procedure provided by the supplier (Innogenetics N.V., Belgium) or by RFLP analysis. For RFLP analysis, HCV genotypes were determined by cleavage of the PCR products with restriction enzymes BstNI, Bsr, HinfI, MaeIII, HaeIII, BstUI and ScrFI. Digests were analyzed by gel electrophoresis and ethidium bromide staining.

30

EXAMPLE II

PRIMER DESIGN AND PSMEA PROCEDURE

In accordance with a preferred embodiment of the invention, the development of PSMEA is based on a single primer extension in the 5'-UR of the HCV genome using pfu DNA polymerase in the presence of only dCTP

and dGTP in the reaction. Thus, under these reaction conditions, primer extension occurs when only the G and/or C nucleotides are added immediately downstream of the 3' end of the primer, since the incorporation of A or T nucleotide would in many instances be prevented by the 3'-5' exonuclease activity of pfu. The primers were designed to meet the following requirements:

1. They must have type-specific sequences; and
2. All primers used for PSMEA should exhibit a similar melting temperature.

The nucleotide sequences of the primers used in this study are shown in Table 1. In the PSMEA procedure, the primer extension reactions contained 20 ng primer, 20-30 ng PCR product, 20 mM of each dCTP and dGTP, 10 mCi of each ³²P-labeled dCTP and dGTP, 1.25 units pfu DNA polymerase and 10 ml 10X pfu reaction buffer (Stratagene). When 5'-end ³²P-labeled primers were used, the ³²P-labeled dCTP and dGTP were omitted, and 100 μM of each dCTP and dGTP were used in the reactions. The primer extensions were performed in a reaction volume of 100 μl in a thermocycler (Perkin Elmer, GeneAmp 9600). Twenty cycles of 94°C for 20 seconds, 64°C for 20 seconds and 72°C for 35 seconds were performed. One microliter of the primer extension products were mixed with 1 μL of the sequencing stop solution (Pharmacia Biotech) and electrophoresed on 8% polyacrylamide 8M urea TBE gels. Extension products were visualized by autoradiography.

30

EXAMPLE III

PCR AMPLIFICATION AND SEQUENCE ANALYSIS

Viral RNA was isolated from 100 μl of serum by treatment with RNazol B (Biotech Laboratories, Houston, Tex.) as previously described in Wilber, J. C., Johnson, P. J., and Urdea, M. S. Reverse transcriptase-

35

PCR for hepatitis C virus RNA, p. 327-331. In D. H. Persing, T.F. Smith, F.C. Tenover, and T.J. White (ed.), *Diagnostic Molecular Microbiology: Principles and Applications*. American Society for Microbiology, Washington D.C. 1993.. RT-PCR was performed as described by Bernier et al. Bernier, L., et al., *J. Clin. Microbiol.* 34: 2815-1818, with a set of primers (see Table 1) that target highly conserved domains within the 5'-UR. If a second round PCR was necessary to provide sufficient cDNA for PSMEA, a pair of nested primers (sense primer -211 to -192 and antisense primer -91 to -74) was used. The nucleotides and primers were removed from the PCR products with the QIAquick™ PCR Purification Kit (QIAGEN), using the procedure recommended by the manufacturer. These purified PCR products were used for PSMEA and for automated sequencing analysis.

EXAMPLE IV

20 GENOTYPING OF HCV ISOLATES BY LiPA AND RFLP

HCV isolates from patients with HCV infection were typed either by the improved Inno LiPA kit II™ using the procedure provided by the supplier (Innogenetics N.V., Belgium) or by RFLP analysis. For RFLP analysis, HCV genotypes were determined by cleavage of the PCR products with restriction enzymes BstNI, Bsr, HinfI, MaeIII, HaeIII, BstUI and ScrFI, (Andonov, A., et al., *J. Clin. Microbiol.* 32: 2031-2034, 1994). Digests were analyzed by gel electrophoresis and ethidium bromide staining.

EXAMPLE V

The accuracy and reliability of PSMEA

To evaluate the accuracy and reliability of PSMEA, 51 HCV isolates from HCV infected individuals in Montreal, Canada, typed by RFLP analysis in the 5' UR

(Andonov, A., et al., *J. Clin. Microbiol.* 32: 2031-2034, 1994) were analyzed with PSMEA in a double blind study. The subtypes 2a and 2c were grouped together when RFLP was used for genotyping of the 51 isolates, since some 2c variants share common ScrFI cleavage sites with 2a variants.

A primer designed with sequence -133 to -113 from this isolate has shown no cross reactivity with other types described in the present study (Table 2), suggesting that most isolates determined as 2a/2c by RFLP have a typical 2a specific sequence, and that the primer 2A can discriminate the majority of subtype 2a from subtype 2c. The results from the analysis of these 51 isolates indicate that 100% of types and subtypes for the isolates determined by PSMEA were matched with the types and subtypes identified with RFLP. In these isolates, there were 14-1a, 14-1b, 5-2a, 5-2b, 1-2c, 10-3a, 1-3b, and 1-6a. LiPA was reported to reliably type the most common genotypes, including some subtypes (Simmonds, P., *Variability of Hepatitis C. Virus. Hepatology* 21: 570-582, 1995). Fifteen (15) isolates were typed by LiPA and evaluated with PSMEA in accordance with the present invention. They include 5-1a, 6-1b, 1-2a, 1-2b, 1-3a, 1-3b. The results from PSMEA showed a 100% agreement with that from LiPA.

A group of five (5) HCV isolates that failed to be typed or subtyped by other methods were clearly identified as 1a or 1b by PSMEA. The results were confirmed by direct DNA sequencing using their PCR products from the 5' UR region (-211 to -71) (Fig. 4), suggesting that results from PSMEA is reliable.

In the present application, the majority of the samples were typed with PSMEA using non-labeled primers and ³²p-labeled dNTPs. Results obtained using ³²p-

labeled dNTPs with unlabelled primers showed the typical patterns of the primer extensions as seen in the results from the reaction with ³²p-labeled primers and non-labeled dNTPs.

5 Accordingly the new genotyping assay, primer specific and mispair extension assay (PSMEA) of the present invention was used to genotype HCV and to detect mixed infections. A total of one hundred and forty six (146) HCV isolates were typed and analyzed
10 with PSMEA, showing that nine of 110 isolates (8.2%) from HCV positive blood donors and six of 36 isolates (16.7%) from thalassaemia patients were found to contain more than one genotypes. The results were confirmed and compared with other current assays
15 including direct DNA sequencing and line probe assay (LiPA). PSMEA of the present invention was found to be more reliable than other assays in detecting mixed infection.

20

EXAMPLE VI

Feasibility of PSMEA for large cohort studies

Some genotypes including 1a, 1b, 2a, and 2b show a broad geographical distribution, and the infection frequency of subtypes 1a and 1b can be over
25 50% in blood donors and patients with chronic hepatitis in the United States (Lau, J.Y., et al., *J. Infect. Dis.* 171: 281-289, 1995), Canada (Bernier, L., et al., *J. Clin. Microbiol.* 34: 2815-1818), (Andonov, A., et al., *J. Clin. Microbiol.* 32: 2031-2034, 1994), and most
30 European countries (Simmonds, P., *Hepatology* 21: 570-582, 1995), (Stuyver, L., Rosseau, et al., *J. Clin. Microbiol.* 34: 2259-2266, 1996). Other genotypes, such as 3a and 3b are less common than 1a and 1b in those countries. However, 3a seems to be quite frequently
35 found in Canada. Genotypes 4, 5a and 6a are only found

in specific geographical regions in the Middle East, South Africa and Hong Kong respectively, but were also infrequently found in some areas of Canada. It is apparent that for each region a strategy for genotyping a large number of HCV isolates by PSMEA has to be designed, based on the genotype distribution and infection frequency with the population. For example, in Canada, over 60% of HCV isolates are genotypes 1a, 1b, which can be identified by primers 1AB, 1BR. However, since genotype 6a was frequently found in some areas of Canada and primer 1AB was cross reacted with 6a, thus all isolates diagnosed as 1a should be retested with primer 6AR for screening of genotype 6a in the first round of testing with PSMEA. The non-typeable isolates using the three primers should be retested with primers 2A and 2B. Thus genotypes 2a and 2b (over 15% of total isolates) can be determined in the second round of testing. The remaining non-typeable isolates should be screened with primers 3A, 3B and 3R. Genotypes 3a and 3b (over 15% of total isolates) can be identified in the third round of testing. After the three round testing, the rest of isolates (less than 10% of total isolates) that cannot be typed by these primers would include some subtypes of type 4, subtype 5a, subtype 2c or other genotypes. Table 3 identifies the infection frequencies of the major HCV genotypes identified by PSMEA, indicating that it is practical and feasible for genotyping a large number of isolates for epidemiology and clinical studies.

All current genotyping assays such as for HCV, including direct DNA sequencing, are not suitable for detection of mixed infections because they are designed for detection of the population-dominant genotype. As indicated in Table 3, HCV mixed infection rate was

higher than expected. A reliable detection of HCV mixed infections by PSMEA in different populations with HCV infection is thus reported.

5

Table 3

The prevalence of HCV mixed genotype infections in different populations determined by PSMEA and direct DNA sequencing

	PSMEA	Direct DNA sequencing
Blood donors	7/72 (9.7%)	ND
Patients with chronic hepatitis C	15/80 (18.8%)	8/80 (10.0%) [#]
Thalassemia patients	6/36 (16.7%)	4/36 (11.1%)

10

[#] The samples determined to contain more than one genotype by direct DNA sequencing were 100% concordant with that determined by PSMEA. Since direct DNA sequencing method is not sensitive enough to detect low levels (<25%) of mixed genotype infections, the percentage of mixed genotype infections determined by direct DNA sequencing is lower than what was found by PSMEA.

15

EXAMPLE VIIDETERMINATION OF HIV-1 MUTANTS

HIV positive sequential plasma samples were collected from patients on the combination therapy with RT and protease inhibitors for greater than three months.

Viral RNA from samples was purified using the QIAamp™ Viral RNA kit. The Pharmacia Biotech First-Strand cDNA Synthesis kit was then used for cDNA synthesis. PCR was performed to amplify the region containing the entire protease and RT regions of HIV-1. The PCR products were purified using the QIA quick™ PCR Purification kit for genotypic analysis with PSMEA, direct DNA sequencing and cloning.

30

PSMEA was performed with the procedure described above. This assay has been developed as a semi-

automated system. Accordingly, a Cy5.5 dye-labeled primer (at the 5'-end of the primer) was used instead of a ³²P labeled primer. Primer extension reactions contained 20 ng of 5'-end 5.5 dye-labelled primer, 20-
5 30 ng of PCR product, 20 µM of each dNTP, 1.25 units of pfu DNA polymerase and 10 µL of 10X pfu reaction buffer (PDI). Primer extensions were performed in a 100 µL reaction volume in a thermocycler (Perkin Elmer, GeneAmp 9600). Twenty cycles of 94°C for 20 seconds,
10 64°C for 20 seconds and 72°C for 35 seconds were performed. One microliter of the primer extension products was mixed with 1 µL of the sequencing stop solution (Pharmacia Biotech) and electrophoresed on 6% polyacrylamide 8M urea TBE mini gels for 10 minutes.
15 Extension products were analysed by automated DNA fragment length polymorphism analysis software in the OpenGene™ automated DNA sequencing system (Visible Genetics).

Both direct DNA sequencing and population based
20 sequencing were performed with an automated DNA sequencer (Visible Genetics) and DNA sequencing kits (Visible Genetics). For the population based DNA sequencing, the PCR products were directly cloned into the TOPO™ TA vector (Invitrogen Corp.). The TTV
25 sequence was amplified from positive colonies of *Escherichia coli* using M13 primers (Pharmacia Biotech). The re-amplified PCR products were sequenced using the same procedure as used for direct DNA sequencing.

Based on the principle of PSMEA, primers can be
30 designed to be either universal for both wild type and mutants or type-specific (i.e. specific to either wild type or mutants). In addition, many options can be explored with different sets of dNTPs and locations of primer binding. To test the feasibility of PSMEA for
35 HIV-1 genotyping, three most common and important

mutation sites of codons 82 (V82), 63 (L63) and 90 (L90) were detected by PSMEA and direct DNA sequencing. Figs. 5A and 5B show an example to indicate the primer design and expected base extensions using different sets of dNTPs for detecting mutation of V82A with a universal primer. In Figs. 5A and 5B, each combination of dNTPs results in a different extension profile, providing a fingerprint for wild type and mutant. In Fig. 5A, extension profile for wild type and mutant are illustrated. Fig. 5B, the peak profiles represent the number of bases extended as detected by automated DNA sequencing using fragment length polymorphism analysis software, with the first peak from left representing unextended primer. When using specific sets of dNTP's; ATC, ATG, ACG and TCG, the primer will extend 3, 1, 0 and 2 bases with wild type. In contrast, extensions of 0, 1, 5, and 2 bases will occur with mutant. These results clearly indicate that the predominant population in this sample was V82A mutant, showing a pattern of 0, 1, 5 and 2 bases extended. However, in the presence of ATC, about 12% of the primer extended, indicating a low proportion of the wild type virus still remained in this patient. Apparently only two sets of dNTPs (ATC and TCG) were needed to determine the levels of mutant and wild type in a mix. In some cases, V82 could mutate to V82I instead of V82A. A primer was designed for detection of V82I mutation using a set of dNTPs (A, T, and C).

It is more difficult to detect drug resistant mutations at codon 63 than other sites because in this case there are 6 combinations of codons for Leucine (L63) and 4 codons for Proline (P63). Since a wild type/mutant mix would almost certainly be caused by a single base substitution, only four variations should be expected, with only CTC/CCC (L63) and CTT/CCT

combinations seen so far, with the former combination being the most common. To overcome this problem, a new type of primer was designed for PSMEA to detect different drug resistant mutations of L63 codon as follows: the target mutation point was included as part of the 3' end of two primers. The 3' end of one primer (PRO63L(G)-R) was a perfect match to the wild type, but not mutant (Figs. 6A(1) and 6A(2)), while the 3' end of the second primer (PRO63P(G)-R) was a perfect match to the nucleotide sequence of mutant, but not wild type (Figs. 6A(3) and 6A(4)). In Fig. 6A, the matched primers should have 4 and 14 bases extension on both L63 and L63P (1) (3), and the primers with mispairs on L63P and L63 were expected to have no extension (2) (4). In Fig. 6B, the primer extended either 4 and 14 bases (second and last peaks from the left) (1) (3), or virtually not at all (2) (4).

If a mismatch occurs on the 3' end of the primer, the *Pfu* will remove the mismatched nucleotides. A mix of 3 dNTP's was added to the reaction in which there are no dNTPs to correct the mismatches on the 3' end of the primer. Thus, primer extension occurs under these circumstances only if the 3' end of the primer was a perfect match to the target mutation point. This results in very little if any, non specific extension, even at annealing temperatures as low as 55°C. When dNTPs (A, T and C) were added, the matched primer was extended with 5 and 14 bases extensions (Figs. 6A(1), (2), (3) and 6B(1), (3)). However the mismatched primer could not be extended because the mismatched nucleotides at 3' end of the primer were removed with no dGTP to repair the mismatch (Figs. 6A(2), 6A(4) and 6B(2), (4)).

Unlike protease codon 63 which has multiple combinations for L63 mutating to L63P, and codon 82

with V82 mutating to V82I/A/others, codon 90 has only one possible combination for L90 mutating to L90M (AAG to ATG). As a result, only one pair of primers is required for detection of this mutation point. Figs. 7A and 7B show that the primer (PRO90L-R) was designed in a reverse direction for detection of L90. Fig. 7A illustrates the expected number of bases extended with matched and mismatched primers on wild type and mutant respectively (1-4). In Fig. 7B, primers PRO90L-R and PRO90M-F on wild type were extended with 4 on wild type (1) and 8 bases on mutant (3).

As expected, the primer was extended with four bases (Figs. 7A(1) and 7B(1)). Under the same reaction conditions, the primer was not extended on mutant L90M due to the T:T mismatch at the 3' end of the primer (Figs. 7A(2) and 7B(2)). Another primer (PRO90M-F) was designed to detect low levels of drug resistant mutant L90M. The primer was extended on L90M mutant with eight bases (Figs. 7A(3) and 7B(3)), but not on wild type due to the second to last nucleotide mismatch (A:A) at the 3' end of the primer (Figs. 7A(4) and 7B(4)).

In order to assess the sensitivity of PSMEA for detection of low levels of mutants in a viral population, an artificial mixing experiment was carried out. PCR products from the protease region of V82 wild type and the V82I mutant were mixed in the following proportions between mutant and wild type: 3.1% (1/32), 1.6% (1/64), 0.8% (1/128) and 0.0% (i.e. 100% wild type). Fig. 8 shows that 0.8% mutant in the mix was clearly detected with PSMEA. The levels at 0.8%-3.1% were not detected by direct DNA sequencing. It has previously been reported that the mixed genotypes or quasispecies could be detected only when mixed

genotype(s) reached levels over 25% (Deeks SG, Abrams DI., *Lancet*, 349: 1489-1490, 1997).

To confirm the sensitivity of PSMEA, a total of 32 isolates from patients being treated with antiviral
5 drugs have been analysed with both direct DNA sequencing and PSMEA for the presence of drug resistant mutations in codon V82, L63 and L90 from the protease region of HIV-1. Table 4 shows a 100% concordance of the genotypic testing results between PSMEA and direct
10 DNA sequencing for detection of predominant population of variants including mutants and wild type.

Table 4

Comparison of the sensitivity between direct DNA sequencing and PSMEA for detecting low levels of drug resistant mutations

5

Sample ID	Direct DNA Sequencing			PSMEA					
	L63/P/C/ L63T (W/M)	V82/I/A (W/M)	L90/M (W/M)	L63 (%)	L63P/ L63C (%)	V82/V82I/V82A (%)			L90/L90M (%)
4B	L63	V82	L90			91	7	2	
6B	L63P	V82	L90	3	97P	96	2	2	
7B	L63C	V82	L90			83	14	3	
8B	L63P	V82	L90	2	98P	89	3	8	
GL	L63P	V82	L90M			97	<1	2	7 93
JB	L63P	V82A/V	L90M/L			31	15	54	56 44
MN	L63P	V82A	L90M	0	100P	22	10	68	5 95
CA	L63P	V82	L90	0	100P	89	9	2	100 0
DS1	L63P	V82	L90			86	12	2	
DS2	L63P	V82	L90	3	97P	95	3	2	
GP	L63P	V82	L90			91	3	6	100 0
AS		V82A				14	4	82	
FP	L63P	V82	L90			90	7	3	100 0
M15-8	L63C	V82	L90	49	51C	93	5	2	
M15-10	L63	V82	L90	73	27C	90	6	4	
M17-17	L63C	V82V/I	L90	50	50C	71	27	2	
M17-22	L63C	V82	L90	48	52C	90	8	10	
M17-25	L63	V82	L90	88	12C	54	17	29	
M17-33	L63T	V82	L90			84	14	2	
M17-35	L63T	V82	L90			81	16	3	
M17-37	L63	V82	L90	94	6C	79	19	2	
M17-41	L63	V82	L90	97	3C	93	4	3	
M17-44	L63P	V82	L90M			93	5	2	
98027	L63	V82	L90	96	4P	89	9	2	99 1
V894713	L63	V82	L90			89	9	2	100 0
AR283	L63P	V82I	L90			20	76	4	100 0
AR929	L63P	V82I/V	L90			33	65	2	100 0
AR2429	L63P	V82V/I	L90			39	60	1	100 0
AP6423	L63L/P	V82	L90			90	8	2	100 0
AP6617	L63P	V82	L90			89	10	1	100 0
AP7010	L63P	V82	L90			90	9	1	100 0
AP7366	L63P	V82	L90			90	8	2	100 0

The percentage of mutant in a mix is calculated as follows:

$$\% \text{ mutant} = (\% \text{ wild type extension} + \% \text{ mutant extension}) \times 100$$

Twenty five (25) (78.1%) of 32 samples
 10 determined as being fully wild type (V82) were found to
 contain either mutants V82I or V82A at various levels
 (1-19%). Different levels (3-27%) of L63P mutant were
 detected by PSMEA in 100% (5/5) of the samples that
 were determined as purely wild type (L63) by direct DNA
 15 sequencing. However, in detecting L90M mutation, the

results showed 86.7 % (13/15) concordance between the two methods.

One of the samples (AR283) was analysed using population based sequencing, direct DNA sequencing and PSMEA to further evaluate the accuracy of PSMEA in detecting low levels of drug resistant mutants. Table 5 shows that PSMEA demonstrated greater concordance with population based sequencing, than direct DNA sequencing for monitoring minor variants. Seventy six percent (76%) and 20% of isolate from AR283 was found to be V82I mutant and wild type V82 respectively by PSMEA, but 100% mutant V82I by direct DNA sequencing. Population based sequencing showed that wild type truly existed at level of 12.5% (4/32). For detection of predominant populations variants (mutant V82I and wild type L90) in the isolate, both direct DNA sequencing and PSMEA were 100% concordant with population based sequencing.

20

Table 5

Evaluation of the accuracy of PSMEA and direct sequencing for detection of low levels of variants with population based sequencing

Method	Genotypes			
	% V82I	% V82	% L90M	% L90
Population based sequencing	87.5(28/32)*	12.5 (4/32)	0.0 (0/32)	100.0 (32/32)
Direct DNA sequencing	100.0	0.0	0.0	100.0
PSMEA	76.0	20.0	0.0	100.0

* Denotes that a total number of mutant or wild type found in 32 cloned PCR products sequenced.

From the above, it is thus apparent that PSMEA is more sensitive than direct DNA sequencing for

detection of low levels of drug resistant mutants. The high degree of sensitivity of PSMEA should allow to more precisely understand how early drug resistant mutations can develop, especially during antiretroviral therapy. For clinics, this may further aid in guiding clinicians in modulating therapeutic regimens before the appearance of phenotypic drug resistance or deterioration in clinical status. With early warning of drug specific mutations, agents can be chosen to impede resistance and minimize cross resistance, yet still have an antiviral effect on the patient's dominant quasispecies. This in turn will hopefully delay therapeutic failure and increase survival.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A primer-specific and mispair extension assay for the determination of genotype, said assay comprising the steps of:
 - a) extending a nucleic acid sequence from a patient sample with a polymerase using a primer specific for a genotype to be determined and an incomplete set of dNTPs, under suitable conditions for obtaining extension products of the primer, whereby at least one of the primer or the dNTPs is labeled;
 - b) characterizing the extension products; and
 - c) comparing the extension products with known nucleic acid sequences of various genotypes for determining the genotype of the nucleic acid sequence extended.
2. The assay of claim 1, wherein the step of characterizing the extension products comprises the step of separating by size said extension products.
3. The assay of claim 1, further comprising before step a) the step of amplifying the nucleic acid sequence.
4. The assay of claim 1, wherein the polymerase is PFU DNA polymerase.
5. The assay of claim 1, wherein the incomplete set of dNTPs contains three different types of nucleotides.
6. The assay of claim 1, wherein the incomplete set of dNTPs contains two different types of nucleotides.

7. The assay of claim 1, wherein the primer is labeled with a radioactive label.


8. The assay of claim 1, wherein one of the dNTPs is labeled with a radioactive label.

9. The assay of claim 1, wherein the primer is labeled with a fluorescent label.

10. The assay of claim 1, wherein steps a), b), c), and d) are automated.

11. The assay of claim 1, wherein the step of characterizing the extension products further comprises after the step of separating by size the extension products the step of sequencing the extension products.

1/10



-113 -108 -99

1a 5'-----TTTGGGCG (T) GCCCCCGCAAGAC-----3'

X← 1BR 5'

1b 5'-----TTTGGGCG (T) GCCCCCGCGAGAC-----3'

XXXCCCGC (G) CGGGGGCGC← 1BR 5'

I' and II'

1a 3'-----AAACCCGC (A) CGGGGGCGTTCTG-----5'

5' 1AB CG (C) GCCCCCGCXX

1b 3'-----AAACCCGC (A) CGGGGGCGCTCTG-----5'

5' 1AB CG (C) GCCCCCGCGX X

III'


-113 -108 -99

1a 5'-----TTTGGGCG (T) GCCCCCGC (A) AGAC-----3'

AAACCCGC (G) CGGGGGCG (C) ← 1BR 5'

Fig. 1


2/10






	-157	-145	-144	
	1a 5'---AGGACCGGGTCCTTTC (.) TTGG-----3'			
I-1		X	← 6AR-1 5'	C, G
I-2		X	← 6AR-1 5'	G, T
	6a 5'---AGGACCGGGTCCTTTC (C A) TTGG-----3'			
I-3		X	← 6AR-1 5'	C, G
I-4		XXG G T	← 6AR-1 5'	G, T
	6a 5'---AGGACCGGGTCCTTTC (C A) TTGG-----3'			
II-1	XGGCCCAGGAAAG	G	← 6AR-2 5'	A, C, G
II-2	XXG	G	← 6AR-2 5'	G
	1a 5'---AGGACCGGGTCCTTTC (.) TTGG-----3'			
II-3		X	→ 6AR-2 5'	A, C, G
II-4		X	→ 6AR-2 5'	G

FIG. 2


3/10

FIG. 3

4/10



II



Expected base extension

dNTPs

ATC	Primer → T CAXX	3
ATG	Primer → T X-XX	1
ACG	Primer → X-X	0
TCG	Primer → T CX--X	2
WT	-----A GTCCACATCCT----- (SEQ ID NO:16)	
ATC	Primer → X X	0
ATG	Primer → G XX	1
ACG	Primer → G CAGGX-X	5
TCG	Primer → G CX--X	2
MU	-----C GTCCACATCCT----- (SEQ ID NO:17)	

5/10




Fig. 5A

Fig. 5B

3' XTCATACTAXTCCATGAGTATCTTTAGACACCTGTATTTCG 5' L63 + PRIMER (1) (SEQ ID NO:18)
 5' AGACAGTATGATCAGGTACTCATAGAAATCTGTGGACATAAAGC 3' PRO63L(G)-R (SEQ ID NO:19)

X

3' GAGTATCTTTAGACACCTGTATTTCG 5' L63P + PRIMER (2) (SEQ ID NO:20)
 5' AGACAGTATGATCAGGTACCCATAGAAATCTGTGGACATAAAGC 3' PRO63L(G)-R (SEQ ID NO:21)

6/10


3' XTCATACTAXTCCATGGGTATCTTTAGACACCTGTATTTCG 5' L63P + PRIMER (3) (SEQ ID NO:22)
 5' AGACAGTATGATCAGGTACCCATAGAAATCTGTGGACATAAAGC 3' PRO63P(G)-R (SEQ ID NO:21)

X

3' GGGTATCTTTAGACACCTGTATTTCG 5' L63 + PRIMER (4) (SEQ ID NO:23)
 5' AGACAGTATGATCAGGTACTCATAGAAATCTGTGGACATAAAGC 3' PRO63P(G)-R (SEQ ID NO:19)

~~SECRET~~ - BA

7/10



FISS-6B

3' **XX**AGACTTCTGAGTCTA**ACCAACGTGAAATTTA** 5' PRO90L-R (1) (SEQ ID NO:24)
 5' --AATCTGAAGACTCAGATTGGTTGCACCTTTAAAT---3' L90 (SEQ ID NO:25)

X

3' TTCTGAGTCTA**ACCAACGTGAAATTTA** 5' PRO90L-R (2) (SEQ ID NO:26)
 5' --AATCTGATGACTCAGATTGGTTGCACCTTTAAAT---3' L90M (SEQ ID NO:27)



5' CTGTCAACATAATTGAAGAAATCTGAT**GACGCAGAXX** 3' PRO90M-F (3) (SEQ ID NO:28)
 3' --GACAGTTGTATTAACTTCTTTAGACTACTGCGTCTAA---5' L90M (SEQ ID NO:29) ⁸/₁₀

X

5' CTGTCAACATAATTGAAGAAATCTGAT 3' PRO90M-F (4) (SEQ ID NO:30)
 3' --GACAGTTGTATTAACTTCTTTAGACAACCTGAGTCTAA---5' L90 (SEQ ID NO:31)


FIG. 7A

9/10



FISS - 7B

10/10



MU ----- \rightarrow T AGTTGTATTAAAXX (SEQ ID NO:32)
 ----- A TCAACATAATTGGAAAGA (SEQ ID NO:33)

WT ----- \rightarrow X
 ----- G -----

FIG. 10

SEQUENCE LISTING

<110> Canadian Blood Services
Hema-Quebec

<120> PRIMER-SPECIFIC AND MISPAIR EXTENSION
ASSAY FOR IDENTIFYING GENE VARIATION

<130> 13453-4PCT

<150> CA2,245,039

<151> 1998-08-13

<160> 33

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> sense universal primer for PCR (first round)

<400> 1

ctcccctgtg aggaactact gtctt

25

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense universal primer for PCR (first round)

<400> 2

ctcgcaagca ccctatcagg

20

<210> 3

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> sense universal primer for PCR (second round)

<400> 3

ccatagtggt ctgcggaacc ggtgagtaca c

31

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense universal primer for PCR (second round)

<400> 4

cccaacacta ctcggcta 18

<210> 5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for PSMEA

<400> 5

ctcaatgcct ggagatttg g 21

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for PSMEA

<400> 6

caccggaatt gccaggacga 20

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for PSMEA

<400> 7

acactactcg gctagcagtc t 21

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for PSMEA

<400> 8

ccactctatg cccggtcatt t 21

<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 9
tatgtccggt catttgggca c 21

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 10
cactctgtgc ccggccattt g 21

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 11
accggaatcg ctgggggtga 19

<210> 12
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 12
accggaatcg ccgggatga 19

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 13
cactactcgg ctagtgatct c 21

<210> 14
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 14
gggggtcctg gaggtgtt 19

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for PSMEA

<400> 15
cattgagcgg gttgatcca at 22

<210> 16
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Extension product of wild type HIV-1

<400> 16
agtccacatc ct 12

<210> 17
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Extension product of mutant type HIV-1

<400> 17
cgtccacatc ct 12

<210> 18
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> L63 + primer sequences

<400> 18
gctttatgtc cacagatttc tatgagtacc tnatcatact n 41

<210> 19
<211> 44
<212> DNA
<213> Artificial Sequence

<220>

<223> pro63L(G) -R

<400> 19

agacagtatg atcaggtact catagaaatc tgtggacata aagc 44

<210> 20

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> L63P + primer sequences

<400> 20

gctttatgtc cacagatttc tatgag 26

<210> 21

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> pro63L(G) -R

<400> 21

agacagtatg atcaggtacc catagaaatc tgtggacata aagc 44

<210> 22

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> L63P + primer sequences

<400> 22

gctttatgtc cacagatttc tatgggtacc tnatcatact n 41

<210> 23

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> L63 + primer sequences

<400> 23

gctttatgtc cacagatttc tatggg 26

<210> 24

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PRO90L-R

<400> 24
atttaaagtg caaccaatct gagtcttcag ann 33

<210> 25
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> L90

<400> 25
aatctgaaga ctcagattgg ttgcacttta aat 33

<210> 26
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> PRO90L-R

<400> 26
atttaaagtg caaccaatct gagtctt 27

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> L90M

<400> 27
aatctgatga ctcagattgg ttgcacttta aat 33

<210> 28
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> PRO90M-F

<400> 28
ctgtcaacat aattggaaga.aatctgatga cgcagann 38

<210> 29
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> L90M

<400> 29
aatctgcgtc atcagatttc ttccaattat gttgacag 38

<210> 30
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> PRO90M-F

<400> 30
ctgtcaacat aattggaaga aatctgat 28

<210> 31
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> L90

<400> 31
aatctgagtc aacagatttc ttccaattat gttgacag 38

<210> 32
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Extension product of a mutant HIV-1

<400> 32
agttgtatta ann 13

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Extension product of a wild HIV-1

<400> 33
tcaacataat tggaaaga 18

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 99/00733

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 30545 A (APPLIED GENETICS INC) 3 October 1996 (1996-10-03) claims 20-36; example 2 ---	1-11
A	BI W ET AL: "Detection of known mutation by proof-reading PCR" NUCLEIC ACIDS RESEARCH, vol. 26, no. 12, June 1998 (1998-06), pages 3073-5, XP002127555 the whole document ---	1-11
A	WO 94 01447 A (EYAL NURIT ;FRIEDMAN MARK M (IL); ERIPHYLE B V (NL)) 20 January 1994 (1994-01-20) claims 1-13; figures 1-4 ---	1-11
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

10/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/CA 99/00733

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 91 13075 A (ORION YHTYMAE OY) 5 September 1991 (1991-09-05) claims 1-16 ---	1-11
P,X	HU YW ET AL: "Primer specific and mispair extension analysis (PSMEA) as a simple approach to fast genotyping" NUCLEIC ACIDS RESEARCH, vol. 26, no. 21, November 1998 (1998-11), pages 5031-5, XP002127556 the whole document -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00733

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9630545 A	03-10-1996	AU 5296496 A US 5976798 A	16-10-1996 02-11-1999
WO 9401447 A	20-01-1994	IL 102382 A AU 4770393 A EP 0648222 A FI 946127 A IL 106199 A IL 111267 A JP 8507198 T NO 945100 A US 5650277 A US 5710028 A	04-08-1996 31-01-1994 19-04-1995 20-02-1995 24-09-1998 14-07-1999 06-08-1996 22-02-1995 22-07-1997 20-01-1998
WO 9113075 A	05-09-1991	AT 180019 T AU 642709 B AU 7235191 A CA 2071537 A DE 69131233 D DE 69131233 T DE 648280 T EP 0648280 A ES 2072235 T FI 923653 A GR 95300047 T HU 211058 B IL 97222 A JP 2786011 B JP 5504477 T NO 923116 A NZ 237134 A PT 96776 A,B	15-05-1999 28-10-1993 18-09-1991 17-08-1991 17-06-1999 04-11-1999 30-11-1995 19-04-1995 16-07-1995 14-08-1992 31-07-1995 30-10-1995 31-08-1995 13-08-1998 15-07-1993 10-08-1992 25-06-1992 31-10-1991